Willmann JK et al. J Clin Oncol 2017; 35(19): 2133-2140. doi:10.1200/JCO.2016.70.8594 Summary Preclinical studies have demonstrated the potential of USMI using MBKDR in cancer imaging; this was the first-in-human clinical trial of this contrast agent in patients with breast and ovarian cancers. Women with focal ovarian or breast lesions were injected with MBKDR (0.03–0.08 mL/kg of body weight), and USMI of lesions were performed 5–29 minutes later. MBKDR was well tolerated in study participants. No serious adverse events were reported, no deaths occurred in the study and no patients discontinued study participation due to adverse events. Successful intravenous administration of MBKDR occurred in all patients with enhancement of the solid portion of ovarian and breast target lesions during the bolus phase within the first 45 seconds. This strategy of targeted USMI with MBKDR for detection of specific receptors may be generalised to the detection and characterisation of other cancer types.